{"id":"real-word-drugs","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT00503139","NCT06698796","NCT06479954","NCT00818207","NCT04398628","NCT07459686","NCT06279221","NCT03185481","NCT01848028","NCT00830128","NCT01463306","NCT01485887","NCT03722966","NCT00895895","NCT06532357","NCT00413699","NCT01302080","NCT00658359","NCT03362502","NCT05549934","NCT07077473","NCT05166135","NCT06962969","NCT01646385","NCT07072793"],"aliases":[],"patents":[],"pricing":[],"allNames":"real word drugs","offLabel":[],"timeline":[{"date":"2010","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit) — Smoking Cessation"},{"date":"2011","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia) — Fibromyalgia"},{"date":"2011","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease) — Alzheimer Disease. Trial terminated early."},{"date":"2022","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dys) — Duchenne Muscular Dystrophy. Trial terminated early."}],"brandName":"real word drugs","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"real word drugs","explanation":"","oneSentence":"real word drugs","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"real-word-drugs","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Familial Mediterranean Fever (FMF )","phase":"preclinical","trialId":"","patients":null,"diseaseId":"unknown","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00503139","phase":"N/A","title":"Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":684,"indication":"Rheumatoid Arthritis","completionDate":"2013-04","primaryEndpoint":"The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing w"},{"nctId":"NCT06698796","phase":"Phase 3","title":"A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":211,"indication":"Dermatomyositis","completionDate":"2027-11","primaryEndpoint":"The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \\[DM\\] or polymyositis \\[PM\\])."},{"nctId":"NCT06479954","phase":"N/A","title":"Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and R","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":1,"indication":"Relapsed and Refractory Multiple Myeloma (RRMM)","completionDate":"2027-02","primaryEndpoint":"To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use."},{"nctId":"NCT00818207","phase":"Phase 4","title":"Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1380,"indication":"Smoking Cessation","completionDate":"2010-03","primaryEndpoint":"This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated t"},{"nctId":"NCT04398628","phase":"N/A","title":"ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders","status":"Recruiting","sponsor":"American Thrombosis and Hemostasis Network","isPivotal":false,"enrollment":3000,"indication":"Hematologic Disorder","completionDate":"2035-06","primaryEndpoint":"In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly."},{"nctId":"NCT07459686","phase":"N/A","title":"An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Coli","status":"Not Yet Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":553,"indication":"Ulcerative Colitis (UC)","completionDate":"2029-01","primaryEndpoint":"A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice."},{"nctId":"NCT06279221","phase":"N/A","title":"Litfulo Capsules Special Investigation","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":487,"indication":"Alopecia Areata","completionDate":"2030-04","primaryEndpoint":"The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug"},{"nctId":"NCT03185481","phase":"Phase 2","title":"Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":5,"indication":"Parkinson's Disease With Motor Fluctuations","completionDate":"2017-10","primaryEndpoint":"The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations."},{"nctId":"NCT01848028","phase":"N/A","title":"PsoBest - The German Psoriasis Registry","status":"Recruiting","sponsor":"Universitätsklinikum Hamburg-Eppendorf","isPivotal":false,"enrollment":3500,"indication":"Psoriasis","completionDate":"2032-12","primaryEndpoint":"Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany."},{"nctId":"NCT00830128","phase":"Phase 3","title":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":106,"indication":"Fibromyalgia","completionDate":"2011-02","primaryEndpoint":"This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00"},{"nctId":"NCT01463306","phase":"Phase 3","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatri","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":605,"indication":"Epilepsy, Partial Seizures","completionDate":"2019-08","primaryEndpoint":"Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seiz"},{"nctId":"NCT01485887","phase":"Phase 3","title":"Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":50,"indication":"Major Depressive Disorder","completionDate":"2014-01","primaryEndpoint":"This is a phase 3, flexible-dose, open-label, multi-center study."},{"nctId":"NCT03722966","phase":"Phase 2","title":"Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)","status":"Terminated","sponsor":"University of Oklahoma","isPivotal":false,"enrollment":34,"indication":"Smoking Cessation","completionDate":"2022-02","primaryEndpoint":"Varenicline is considered to be a first-line tobacco cessation treatment."},{"nctId":"NCT00895895","phase":"Phase 2","title":"Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":526,"indication":"Alzheimer Disease","completionDate":"2011-05","primaryEndpoint":"The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels."},{"nctId":"NCT06532357","phase":"N/A","title":"A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1536,"indication":"Migraine","completionDate":"2024-06","primaryEndpoint":"The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024."},{"nctId":"NCT00413699","phase":"Phase 3","title":"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis","status":"Completed","sponsor":"Pfizer","isPivotal":true,"enrollment":4488,"indication":"Arthritis, Rheumatoid","completionDate":"2016-11","primaryEndpoint":"The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis."},{"nctId":"NCT01302080","phase":"N/A","title":"Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":941,"indication":"Obsessive Compulsive Disorder","completionDate":"2020-09","primaryEndpoint":"To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) w"},{"nctId":"NCT00658359","phase":"Phase 2","title":"Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Tran","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":178,"indication":"Kidney Transplantation","completionDate":"2015-03","primaryEndpoint":"This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will foll"},{"nctId":"NCT03362502","phase":"Phase 1","title":"A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dys","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":23,"indication":"Duchenne Muscular Dystrophy","completionDate":"2022-03","primaryEndpoint":"This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non"},{"nctId":"NCT05549934","phase":"Phase 2","title":"Ritlecitinib for Cicatricial Alopecia","status":"Completed","sponsor":"Emma Guttman","isPivotal":false,"enrollment":50,"indication":"Cicatricial Alopecia","completionDate":"2025-03","primaryEndpoint":"Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and "},{"nctId":"NCT07077473","phase":"N/A","title":"Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever","status":"Recruiting","sponsor":"Tongji Hospital","isPivotal":false,"enrollment":12,"indication":"Familial Mediterranean Fever (FMF )","completionDate":"2026-12","primaryEndpoint":"retrospective observe the efficacy and safety of different drugs used in familial Mediterranean fever (FMF) cases in real-world"},{"nctId":"NCT05166135","phase":"N/A","title":"Latin American Real-world Study in Acute Leukemia","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":589,"indication":"Acute Myeloid Leukemia","completionDate":"2022-11","primaryEndpoint":"The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and d"},{"nctId":"NCT06962969","phase":"N/A","title":"A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiv","status":"Not Yet Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":1000,"indication":"Advanced or Metastatic Breast Cancer","completionDate":"2025-11","primaryEndpoint":"The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice."},{"nctId":"NCT01646385","phase":"N/A","title":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":6393,"indication":"Rheumatoid Arthritis","completionDate":"2012-08","primaryEndpoint":"This study will assess the rates of serious adverse events and death in adult rheumatoid arthritis patients treated with etanercept over the long-term in real-life clinical practice."},{"nctId":"NCT07072793","phase":"N/A","title":"A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate CO","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":131005,"indication":"COVID-19 (Coronavirus Disease 2019)","completionDate":"2024-11","primaryEndpoint":"The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL1863515"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"Sirolimus is a hydrolytic enzyme drug that targets methotrexate, and it is being studied for the treatment of Peripheral Artery Disease, Atherosclerosis, and other conditions. It is administered via a Neo sirolimus coated PTA balloon catheter, such as the Xtreme Touch, in clinical trials.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}